Skip to main content

BriaCell Therapeutics: Bottom 25 Performing Stocks Year-to-Date on TSX (BCT)

AI-generated - The Globe and Mail - Thu Aug 15, 7:34PM CDT

BriaCell Therapeutics Corp is among the group of bottom performing stocks year-to-date on the Toronto Stock Exchange. This means each stock on this list has seen its share price decrease at a faster rate than the rest of the market so far this year.

This report is generated monthly. It highlights the 25 companies with the greatest percentage decrease in share price year-to-date. Stocks in this category are generally sold to preserve capital or held for speculation.

Companies experiencing dramatic increases in share price can do so for a variety of reasons – including bearish changes in sector outlook, or the company is experiencing financial difficulties generally due to an inability to service its debt.

SymbolNameTotal ReturnPeriod
VGCXVictoria Gold Corp-93.103448YTD
BCTBriaCell Therapeutics Corp-90.25641YTD
APSAptose Biosciences Inc-80.298507YTD
CJR-BCorus Entertainment Inc-79.577465YTD
CHWChesswood Group Ltd-78.117359YTD
NCUNevada Copper Corp-76.923077YTD
CRWNCrown Capital Partners Inc-75.736568YTD
LPENLoop Energy Inc-73.333333YTD
WRXWestern Resources Corp-73.333333YTD
NUMINuminus Wellness Inc-72.727273YTD
AVNTAvant Brands Inc-67.857143YTD
AMMAlmaden Minerals Ltd-67.567568YTD
SVASernova Corp-67.142857YTD
LEVThe Lion Electric Co-66.101695YTD
TAIGTaiga Motors Corp-65.730337YTD
LACLithium Americas Corp-64.235294YTD
NANONano One Materials Corp-63.070539YTD
GFPGreenFirst Forest Products Inc-62.631579YTD
TIXTTELUS International (Cda) Inc-62.390158YTD
DNDelta 9 Cannabis Inc-60YTD
EXROExro Technologies Inc-59.375YTD
SOT-UNSlate Office REIT-59.259259YTD
LAACLithium Americas (Argentina) Corp-57.964072YTD
SMCSulliden Mining Capital Inc-57.142857YTD
GLOGlobal Atomic Corp-56.834532YTD

All data provided as of August 15, 2024.

More about BriaCell Therapeutics Corp

BriaCell Therapeutics Corp is an immuno-oncology-focused biotechnology company. The group develops targeted and safe approaches for the management of cancer. BriaCell is conducting a Phase I/IIa clinical trial of Bria-IMT in metastatic breast cancer. Additionally, it is developing Bria-OTS, off-the-shelf personalized immunotherapy, for the treatment of advance-stage breast cancer by matching the patient's HLA type.

BriaCell Therapeutics Corp is listed under BCT on the Toronto Stock Exchange.

Artificial intelligence at Report on Business

Report on Business scans market data using algorithms to process large quantities of information. The results are specialized reports produced through automation. Ongoing ROB project experiments that leverage artificial intelligence include valuation screens across 14 categories and end-of-day Closing Summary reports for all North American securities.